Ep 87: INTerpath-001 Press Release - August 2026

<p>In this episode, Sapna and James discuss the INTerpath-001 press release describing primary endpoint (RFS) and key secondary endpoint (DMFS) findings from the randomized phase 3 study of individualized neoantigen therapy plus pembrolizumab for resected stage IIB to IV melanoma. No data were shared, only descriptive findings of &quot;statistically signficant&quot; and &quot;clinically meaningful&quot; results. As James puts it, one of these is binary, the other is subjective. </p>